Medically reviewed by Mark Strehlow, MD, Medical Director — November 2026
AOD-9604 is a synthetic peptide, a modified piece of the tail end of human growth hormone, developed in Australia as an obesity drug and now promoted for fat loss, mostly as an injection under the skin. Tested in people, by mouth: the largest trial, of 502 adults with obesity over 24 weeks, missed its weight-loss goal (the developer’s announcement reads “Not met.”), and the developer ended its obesity programme; the same trials found no rise in IGF-1 or blood sugar, growth hormone’s best-known unwanted effects. The evidence in people stops at nine trials run by its developers, 993 people with placebo groups counted, all by mouth or by infusion into a vein: no study in people of an injection under the skin, a cream or an injection into a joint was found.
This review, part of our peptide library, sets out what has been tested and what hasn’t. Our providers prescribe some of the peptides reviewed in this library, and we earn money from that care.
At a glance
- FDA status
- Not FDA-approved; outside the FDA’s and HHS’s compounding policies. FDA advisers voted 12 to 0 against listing it.
- Evidence in people
- Nine developer-run trials, 993 people, by mouth or vein. No significant benefit over placebo on any main outcome.
- The claim you’ve heard
- Burns fat: the largest trial, by mouth, missed its goal; injection under the skin was never tested in people.
- Doses tested in people
- 0.25 to 60 mg a day by mouth; single doses by vein. None by injection under the skin.
- Sport
- Prohibited at all times: WADA’s 2026 and 2027 Lists name it among growth hormone fragments (class S2).
What AOD-9604 is
AOD-9604 is a chain of 16 amino acids that the FDA describes as “a synthetic fragment of human growth hormone (hGH) (15 amino acids: 177-191) with an additional tyrosine at the N-terminal end”: the last 15 of the hormone’s 191, plus a tyrosine at the front. It is not growth hormone: in lab studies it did not bind the growth hormone receptor, and in the trials it did not raise IGF-1 (the growth signal that growth hormone raises).
Two codes, one substance. Metabolic Pharmaceuticals of Melbourne tested it for obesity; Lateral Pharma later tested it for pain as LAT8881. That the two codes are one substance rests on the sponsor’s own registry entries: the EU register gives the product code as “LAT8881 (previously known as AOD9604)”, and the Australian registry writes “LAT8881 (formerly known as AOD9604)”. The ClinicalTrials.gov records say only “LAT8881”.
Not the same thing. “HGH Fragment 176-191” names a different sequence: it begins with phenylalanine where AOD-9604 has tyrosine, and WADA lists the two separately. The names are used interchangeably online and in at least one journal paper, so a label does not show which sequence a vial holds.
Where it stands with the FDA
Status checked: November 19, 2026.
In plain words: AOD-9604 is not an FDA-approved medicine and is not on the FDA’s list of ingredients for compounding (making a medicine for one patient on a prescription); the FDA’s advisory committee voted against adding it, and the FDA has issued no rule either way. It is outside a draft compounding policy from HHS, the federal department the FDA belongs to, and the FDA says it lacks the information to know whether it would cause harm in people.
As of November 19, 2026, AOD-9604 is not an FDA-approved drug and is not on the FDA’s list of bulk drug substances that can be used in compounding under section 503A. The FDA’s advisory committee voted against adding it on December 4, 2024 (0 in favor, 12 against; the vote is a recommendation, and the FDA has issued no rule adding it or excluding it), it is in none of the categories of the FDA’s interim compounding policies (the FDA removed it from Category 2 in September 2024 “because the nominations were withdrawn by the nominators”), and it is not one of the six peptides named in HHS’s October 2026 draft interim policy; the FDA’s guidance says a drug compounded from a substance in this position “is not eligible for the exemptions in section 503A and may violate the FD&C Act.” The FDA says it “lacks sufficient information to know whether the drug would cause harm when administered to humans” and “has also identified serious adverse events that may be associated with AOD-9604, though causality is not clear.” The FDA’s review proposed “not adding AOD-9604 acetate or AOD-9604 (free base) to the 503A Bulks List” and found “a lack of evidence to support the effectiveness of AOD-9604 (free base) and AOD-9604 acetate for the treatment of obesity” by any route.
Section 503A is the compounding section of the federal Food, Drug, and Cosmetic Act (the FD&C Act). Category 2 held nominated substances for which the FDA “has identified significant safety risks”; leaving it did not make AOD-9604 eligible.
The “GRAS” claim. GRAS, “generally recognized as safe”, is a term of food law. No notice for AOD-9604 is in the FDA’s inventory of GRAS notices (searched November 19, 2026); the “USA GRAS Status” one of its nominators cited to the FDA comes from a 2012 announcement by the peptide’s developer of “a self-affirmed conditional GRAS status” for use as a food ingredient, and a member of the FDA’s staff told the advisory committee that AOD-9604 “is not currently listed on FDA’s GRAS list and has not been through FDA’s GRAS determination, based on our search.”
HHS’s draft interim policy. Announced on October 30, 2026, it names six peptides; in announcing it, HHS said it “does not intend to take enforcement action” when its conditions are met. AOD-9604 is not one of the six, and the policy is not FDA approval.
Sport. WADA’s 2026 and 2027 Prohibited Lists name AOD-9604 in class S2, prohibited at all times, among “growth hormone fragments, e.g. AOD-9604 and hGH 176-191”.
Claims you’ll see, and why sources disagree
Pages disagree for three reasons.
- The weight results were never published in a journal. So a capsule trial that missed its primary analysis is presented as a success, and as support for injections.
- Other molecules stand in for this one. A 2000 study of the fragment without the tyrosine (AOD-9401) is cited as AOD-9604 research.
- Citations don’t hold up. A telehealth marketing article cites the largest trial as “Ng et al. 2008 Obesity”; the result it gives is right, but no such paper exists.
Where this review says “not tested in people”, that is not the same as “doesn’t work”. It cuts both ways: not shown to help, and not shown to be safe.
| Claim | Level of evidence | Verdict |
|---|---|---|
| It burns fat, as “just the fat-burning piece of HGH without the rest” | Tested in people, by mouth; animal studies | Not supported by mouth: the largest trial missed its goal, and body fat by scan showed “No relevant findings.” Under the skin: not tested in people. The trials did find no rise in IGF-1 or blood sugar. |
| It repairs cartilage, joints and bone | Animal studies: one rabbit study | Not tested in people. The one rabbit study injected the knee (see the animal studies). The bone claim rests on a company statement about unpublished animal work. |
| It has “rare FDA approval” or “GRAS (Generally Recognized as Safe) status”, so it is safe | The regulatory record | Not FDA-approved. The GRAS status was the developer’s own conclusion about a use in food; it says nothing about an injection. |
| It raises growth hormone or builds muscle | None found, in people or animals | No study of muscle was found, and it did not raise IGF-1 in people. |
| It is safe, “studied in multiple human clinical trials involving thousands of participants” | Tested in people: 893 in six obesity trials, up to 24 weeks by mouth | Not established. By mouth, the developer’s summary reports adverse events at rates similar to placebo, with one unresolved cluster of serious events. Under the skin: no safety data. |
What the evidence consists of
Tested in people
Nine randomized, placebo-controlled trials, all sponsored by the developers: six in the obesity programme (2001 to 2006) and three for pain as LAT8881 (2019 to 2023). None is published as an effectiveness paper: weight results come from the developer’s announcements and the FDA’s account of two reports we could not open, pain results from the sponsor’s registry entries, and safety for the first six from one paper by company staff and consultants. The FDA’s 2024 review does not mention the pain trials.
| Study | People | Design | What happened | Limits |
|---|---|---|---|---|
| Two early studies by vein | 15 healthy men; 23 men with obesity | Single infusions a week apart, with placebo | First: “No significant glycerol, glucose or IGF-1 trends”. Second: weight fell “on average 0.58 kg over 3 weeks, but this was not statistically different from placebo” | Single doses; the weight result is second-hand, from a 2004 drug profile |
| Two early studies by mouth | 17 and 36 men with obesity | First: single capsule doses two weeks apart. Second: capsules daily for seven days | First: “no statistically significant weight loss compared with placebo”. Second: 1 kg lost at the lowest dose, 0.6 kg on placebo | Second-hand, from the 2004 profile; no statistics for the second |
| 12-week trial | 300 adults with obesity | Capsules daily: five dose levels or placebo, 50 each | Most weight lost at the lowest dose, which “fell short of significance (p=0.1, p=0.05 required) on the primary analysis” | No dose-response |
| 24-week trial | 502 adults with obesity | Tablets daily: three dose levels or placebo, with a diet and exercise programme | Primary endpoint “Not met.”; weight loss beyond the programme “was less than 1 kg in all dose groups” | 357 attended the last visit |
| Nerve-pain trial | 53 adults | Crossover: capsules or placebo, four weeks each | Pain (0 to 10) fell 0.87 against 0.74 on placebo: difference -0.14 (95% CI -0.76 to 0.49; p = 0.67) | Per-protocol analysis of 50 |
| Migraine trial | 21 adults; 17 completed | Crossover: one dose or placebo at the start of an attack | At two hours pain fell 1.8 against 0.8: difference -0.89 (95% CI -2.11 to 0.32; p = 0.1488) | No sample-size calculation; registered after it began |
| Leg-pain trial by vein | 9 healthy volunteers (8 dosed), then 17 adults with sciatica-type pain | Single infusions or placebo | At one hour pain fell 1.1 against 0.6 (p = 0.5903); no posted comparison was significant. A leg-stretch pain measure leaned the peptide’s way, with no statistics posted | Closed to enrolment after a planned interim analysis |
Weight. The 24-week trial was sized for an 80% chance of detecting 1.8 kg more weight loss than placebo; its announcement shows group averages only as a graph. Waist, body fat by DEXA scan, glucose and lipids showed “No relevant findings.” The developer saw a possible “effect with moderate weight loss effort in females”: a subgroup observation in two trials that missed their goals, never tested in a trial designed for it. No published measurement of fat breakdown in people was found.
Pain. The nerve-pain interval is compatible with a small benefit, none, or placebo doing better, and excludes the one-point difference the trial was sized to detect; the migraine interval is wide: 17 people completed.
Reported in people
No uncontrolled study, case series or case report was found.
Animal studies
- Weight. Obese rats given the peptide by mouth for 19 days gained less than half the weight controls gained (15.8 against 35.6 g), and obese mice gained less over 14 days: slower weight gain in genetically obese rodents, not weight loss. The FDA noted that “none of the studies assessed dose-response relationships”.
- Joints. In the one study, 32 rabbits with chemically damaged knees had four weekly injections into the joint. The peptide alone scored no better than hyaluronic acid alone; the two together scored best. The developer supplied the peptide.
Lab studies and how it is thought to work
The FDA: “The molecular target(s) and the mechanism(s) of action underlying the pharmacological effects of AOD-9604 remain unknown.”
Beta-3 receptors on fat cells (animal studies). Marketing pages state “beta-3 receptor activation” as fact; the mouse study’s authors concluded that the effects “are not mediated directly through the beta(3)-AR”.
Who produced the research
Every study showing a biological effect of AOD-9604 comes from its inventors or developers, or was done with their material and help; none has been independently repeated. An all-positive animal record tied to its developers, without a dose-response, is itself a reason for caution.
Dosing: what has been tested, what is used, and what the reasoning supports
This section reports and reasons; it recommends nothing. The trials compared several doses with placebo, by mouth and as single doses into a vein, and none did significantly better on a primary efficacy outcome; no study has given any dose under the skin, so no dose can be called optimal.
Doses tested in people
By mouth: 9, 27 and 54 mg as single doses (17 men) and daily for seven days (36 men; a 2004 drug profile gives “10, 30 or 60 mg”, per the FDA); 1, 5, 10, 20 or 30 mg once a day for 12 weeks (300 adults); 0.25, 0.5 or 1 mg once a day for 24 weeks (502 adults); 30 mg twice a day for four weeks (53 adults); and one 60 mg dose at the start of a migraine (21 adults).
By vein, single doses only: 25 to 400 micrograms per kilogram of body weight (15 men); 25, 50 and 100 micrograms per kilogram (23 men); and 0.8, 1.2 and 1.8 mg per kilogram (8 volunteers, then 1.8 mg per kilogram in 17 patients).
No dose has been tested in people by injection under the skin or into muscle, on the skin as a cream, into a joint, as a lozenge or dissolving tablet, for longer than 24 weeks, with another peptide or drug, or under age 18; nor any dose of “hGH fragment 176-191”.
Doses in common use
These are amounts in circulation: practice that no trial set, reported with where each comes from and how it compares with what was studied.
- About 250 to 500 micrograms under the skin, once a day. The recurring figure on clinic, seller and protocol pages: a telehealth marketing article states “The most common subcutaneous dose used in peptide practice is 300 mcg once daily” (mcg: micrograms), and a protocol site “250 – 500 mcg Once daily”. No study in people gave any amount by this route; the figures match the two lowest tablets of the 24-week oral trial, which missed its goal.
- Cycles and timing. The same article describes “Cycling 8-12 weeks on and 4 weeks off”, and the FDA found in 2024 that “Some wellness clinic websites recommend that the peptide is to be injected 30 minutes prior to eating”. No study tested a cycle or a timing.
- Other figures. A peptide information site with a store lists tiers up to “1,000mcg/day — Matches the oral tablet dose from the trials; never tested by injection” and a scale worked from “3–4 mcg/kg”; a supplement company’s blog lists “Joint/cartilage repair protocols 200–300 mcg 1× daily (subQ) 4–6 weeks”. The only per-kilogram doses in the trials went into a vein, and the only joint study injected a rabbit’s knee.
- Strengths in the FDA’s records. The withdrawn nominations proposed “1,200 mcg/mL for subcutaneous (SC) injection, 600 mcg oral capsule, and 600 mcg/gm topical cream”: product strengths in a regulator’s record, not doses, and only the capsule falls among amounts a trial gave.
What the pharmacology supports, and what it doesn’t
- Amount (measured in people). The 12-week trial reported its largest effect at the lowest of five doses, “with a non-linear dose response” in the FDA’s words, and the follow-up at lower doses missed. More is not known to be better; the record supports no amount.
- Frequency (measured in animals; then inferred). No half-life has been measured in a person: after an infusion “Terminal half-life could not be determined”, and after a 30 mg capsule “the majority of samples were below the limit of quantification.” In pigs dosed by vein it was about 3 minutes. A peptide gone from the blood in minutes could act only through something longer-lasting or a breakdown product, as the later developer proposes from pain experiments in rats; neither is shown in people. Once-daily and twice-daily trials found no benefit either way, so the reasoning supports no schedule.
- Route (inferred). If little intact peptide reaches the blood from a capsule, an injection under the skin could deliver far more than a tablet of the same nominal amount, by a route the FDA says “is associated with increased immunogenicity compared to IV” (immunogenicity: an immune reaction to the peptide). So the trials’ safety findings do not transfer to injections, and their failure by mouth does not show that an injection would fail.
- Duration (convention). Cycles and weeks off are convention: the longest trial ran 24 weeks, by mouth, and no source gives a reason for the off-period.
- Monitoring (inferred). None is established. The signals and gaps set out under Safety point, by inference, to blood pressure and pulse, blood sugar in people with diabetes, liver tests, bone, new growths and allergic reactions.
Nobody knows what an injection under the skin does in a person: the blood level, the effect and the safety are all unmeasured.
What common protocols get wrong
- Trials by mouth cited for injections. A supplement company’s blog calls 200 to 500 micrograms under the skin “Standard Clinical Dosage” and says “Clinical trials investigating obesity used these dosing ranges” and “Most obesity studies used daily dosing for 12 weeks”. No trial injected it under the skin, and one of the six obesity trials ran 12 weeks. An informational site lists the vein doses as “for subcutaneous and intravenous administration”; they went into a vein only.
- A missed trial cited as a win. A peptide information site with a store says the 12-week trial “found significant fat loss at 1mg (1,000mcg)/day” and “showed 1mg/day as optimal”. That group fell short of significance, no fat result has been published, and the next trial, at 0.25 to 1 mg, missed.
- Milligrams carried between routes. A telehealth company, withdrawing its own injection schedule, wrote: “An oral trial cannot be converted into a subcutaneous dose by matching the number of milligrams.” One article’s “The injected route is far more efficient on a milligram basis” has no study behind it, and its “1 mg to 25 mg per day” for the oral trials should read 0.25 to 54 mg.
- Animal figures given as human. A protocol site states a plasma half-life of “~3-4 minutes” with no species; it comes from pigs and from rat plasma in a tube. “The case for splitting is the short half-life”, says one article: a guess offered as a reason.
- The record misdescribed. A protocol site says “Phase 3 trials for obesity were not completed” (none was begun) and reports finding no registered trial (the 24-week trial is registered, and three more as LAT8881).
The dose is the prescriber’s decision for one patient.
Safety, and who should be most cautious
By mouth. In the developer’s summary, which gives few of the underlying numbers, adverse events came at similar rates on the peptide and on placebo for up to 24 weeks; headache was the commonest (42.6% of all participants in the 12-week trial). The highest oral dose, 54 mg, brought more headaches, diarrhoea and flatulence, and two serious events followed single 54 mg doses: diarrhoea judged “possibly related” and a pneumonia judged “unrelated”. No antibodies to the peptide were detected in the subsets tested. The four-week pain trial recorded no serious event.
The unresolved question. In the 12-week trial five serious events were reported, all in people on the peptide: basal cell carcinoma, a lipoma and squamous cell carcinoma at 20 mg, breast cancer at 5 mg and malignant melanoma at 10 mg. By design, 250 people were on the peptide and 50 on placebo. The investigator judged none related, because none occurred in the highest dose group. The FDA: “information is insufficient whether these various types of cancers were unrelated to AOD-9604.” In the 24-week trial serious events were reported by 10 of 377 people on the peptide and 8 of 125 on placebo. No source says the peptide caused any of these.
By vein. Single doses, no serious event. Chest tightness, graded severe and “possibly related”, followed one dose; 5 of 23 men reported mild or moderate euphoria on the peptide and none on placebo; low blood sugar was recorded three times among 15 healthy men, treatment and dose not specified; and at the highest dose in the latest trial two of six volunteers reported six kinds of event between them, among them a fast heartbeat, flushing and chest discomfort. The FDA’s summary lists chest tightness among serious events of oral use; the paper it relies on, and the same FDA paragraph further on, place it after a dose into a vein, graded severe, not serious.
By injection under the skin. No safety information was found. The FDA: “FDA did not find information on the proposed subcutaneous and transdermal use of AOD-9604 (free base) or AOD-9604 acetate in humans” (transdermal: through the skin). Of its empty adverse-event database search it wrote: “the lack of reports for AOD-9604 does not imply that the substance is safe or lacks toxicities.”
Animal studies. The developer’s toxicology paper, which has no data tables, found “no evidence of genotoxicological or toxicological concerns”. The FDA did not accept that: a bone-marker change in rats “might represent negative effects of AOD-9604 on bone health”, for liver changes in monkeys “the possibility cannot be ruled out” of “a clinically relevant nonclinical safety signal”, and positive genotoxicity signals “cannot be regarded as biologically insignificant” (genotoxicity: damage to genetic material). It found no studies of reproduction, of cancer risk, or of repeated dosing under the skin.
Theory, labelled as theory. On reasoning alone, the people with most reason for caution are those with a history of cancer, those with high blood pressure, and anyone using an injected product. The first rests on the events above and the absence of any study of cancer risk (against it, the peptide did not bind the growth hormone receptor in lab studies or raise IGF-1 in people); the second on the mechanism proposed in mice and on vital signs the trials never reported; the third on the absence of safety data for injections under the skin.
| Situation | What is known | Basis |
|---|---|---|
| Pregnancy, breastfeeding | No human data; the FDA “did not identify nonclinical developmental and reproductive studies” | The FDA’s evaluation |
| Under 18 | Not studied | Trial records |
| Diabetes, high blood pressure, regular medicines | Excluded from the largest trial; the four-week pain trial enrolled people with diabetes | Registry records |
| Use beyond 24 weeks | Not studied. The FDA: “there is insufficient information to support patient safety for the long-term use” | The FDA’s evaluation |
| Tested athletes | Prohibited at all times (class S2) | WADA |
Product quality
- Products analysed. A Belgian government laboratory (2018) screened the ten falsified peptide drugs it met most often and found “a high variation in amount of drugs per unit and a low purity (ranging between 5% and 75% for cysteine containing peptides)”, with arsenic and lead in some samples at up to ten times the limit for injected drugs. AOD-9604 contains cysteine, but the abstract does not name the ten, so whether that range includes it is unverified. No published measurement of the purity, content or sterility of AOD-9604 from US sellers or compounders was found.
- FDA records. The FDA found the bulk ingredient “not physically and chemically well characterized”. Two recalls of compounded AOD-9604 injections, of 1,316 vials and of 3 vials, were for “Lack of Assurance of Sterility”: a finding about sterile production, not about AOD-9604 as a substance.
- “Research use only”. Of such labels the FDA wrote, in a December 2024 letter to an online peptide seller that does not name AOD-9604: “evidence obtained from your website establishes that your products are intended to be drugs for human use.”
What we make of it
This section is our reading of the evidence. It is a judgment, not a finding.
For AOD-9604’s main claim the trials were done, by the company with most to gain, and they missed: by mouth, we read the record as showing no meaningful weight loss. Injected under the skin, the form mostly sold, it is unproven and experimental: not shown to help and not shown to be safe.
A benefit from injection is not ruled out: obese rodents gained less weight, women in two trials showed a signal nobody followed up, and an injection may deliver more intact peptide than a capsule. Those are reasons to run a trial, not to expect a result. The claims run well ahead: fat loss credited to clinical trials, joint repair to one rabbit study, and the safety of an injection to a conclusion about food.
What would have to be true: a blinded trial in which AOD-9604 injected under the skin reduces body fat more than placebo, with its safety recorded, and products that contain what the label says.
For whom it might ever be considered, after what, with what monitoring and when to stop are our Medical Director’s to state.
Peptide care at Rock Creek Wellness
Our peptide care starts with lab tests and a visit with one of our providers. The provider decides whether any peptide suits you, and which one; you don’t choose from a menu. How that care works is set out on our peptide therapy page, along with the other reviews in this library. What Peptide Care costs is on the same page.
So that you can weigh this review knowing our interest: RCW’s providers prescribe some of the peptides reviewed in this library, and RCW earns money from that care.
What would change this review
- A trial in people of AOD-9604 injected under the skin. None was found in ClinicalTrials.gov or the EU’s register (searched November 19, 2026).
- Publication of the developers’ results. The developer wrote in 2014 of a “manuscript in preparation”; none is in PubMed.
- Rulemaking. The FDA has issued no rule adding AOD-9604 to its list or excluding it.
Common questions
Does AOD-9604 work for fat loss?
By mouth, the trials did not show it: the largest, in 502 adults over 24 weeks, missed its weight-loss goal. By injection under the skin it has never been tested in people, so that question is open in both directions.
Is AOD-9604 safe?
That is not established. By mouth, the developer’s summary reports side effects at rates similar to placebo for up to 24 weeks, with one unresolved cluster of serious events. For injection under the skin, no safety information was found.
Is AOD-9604 FDA-approved, or “GRAS”?
It is not FDA-approved, and no GRAS notice for it is in the FDA’s inventory. The “GRAS” status was the developer’s own conclusion in 2012 about a use in food, not a finding about an injection.
Can a doctor prescribe AOD-9604?
The federal sources we read give no yes or no about prescribers. AOD-9604 is not FDA-approved, so a prescription would be for a compounded medicine, and the FDA’s guidance says a drug compounded from a substance in its position “is not eligible for the exemptions in section 503A and may violate the FD&C Act”.
How much AOD-9604 do people take, and how often?
The trials gave 0.25 to 60 mg a day by mouth, or single doses into a vein, and no dose did significantly better than placebo on a main outcome. Clinic, seller and protocol pages state about 250 to 500 micrograms under the skin once a day: practice no trial set, by a route no study in people has used. The dose is the prescriber’s decision for one patient.
Sources
Show all 34 sourcesHide sources
- December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee: FDA Briefing Document for AOD-9604 Related Bulk Drug Substances. US Food and Drug Administration, 2024.
- Pharmacy Compounding Advisory Committee, December 4, 2024: transcript, morning session. US Food and Drug Administration, 2025.
- Pharmacy Compounding Advisory Committee, December 4, 2024: Minutes. US Food and Drug Administration, 2024.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. US Food and Drug Administration, 2026.
- Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. US Food and Drug Administration, 2025.
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. US Food and Drug Administration, 2026.
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (category list), “Updated September 27, 2024”. US Food and Drug Administration, as captured by the Internet Archive, 2024.
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, 91 FR 68526, FR Doc. 2026-22192). Federal Register, 2026.
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. US Department of Health and Human Services, 2026.
- GRAS Notices inventory. US Food and Drug Administration, 2026.
- AOD9604 Receives GRAS Status (announcement to the Australian Securities Exchange). Calzada Limited, 2012.
- openFDA drug enforcement reports, product description “AOD-9604”. US Food and Drug Administration, 2026.
- Warning letter: Xcel Research LLC, 694608. US Food and Drug Administration, 2024.
- WADA 2026 Prohibited List; WADA 2027 Prohibited List. World Anti-Doping Agency, 2025 and 2026.
- EU Clinical Trials Register, trial record 2018-004534-15 (GB). European Medicines Agency, 2019.
- Oral LAT8881 in Neuropathic Pain (NCT03865953). ClinicalTrials.gov, 2021.
- A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine (NCT04153409). ClinicalTrials.gov, 2021.
- A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain (NCT05298306). ClinicalTrials.gov, 2024.
- The effect of AOD9604 on weight loss in obese adults (ACTRN12605000067673; “The ‘Options’ Study”; METAOD006). Australian New Zealand Clinical Trials Registry, 2005.
- A study of the effect of oral LAT8881 on acute migraine headache (ACTRN12619001369112). Australian New Zealand Clinical Trials Registry, 2019.
- Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta, 2018.
- Global Substance Registration System, record LAT-8881, UNII 7UP768IP4M. US National Institutes of Health (NCATS), read 2026.
- UniProt P01241, SOMA_HUMAN, Somatotropin. UniProt Consortium, read 2026.
- Metabolic’s obesity drug – Phase 2B clinical trial results (ASX announcement, Melbourne, 21 February 2007). Metabolic Pharmaceuticals Limited, 2007.
- Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism, 2013.
- Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. Journal of Endocrinology and Metabolism, 2014.
- AOD-9604 Metabolic. Current Opinion in Investigational Drugs, 2004.
- Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 2000.
- The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology, 2001.
- Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity and Related Metabolic Disorders, 2001.
- Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. American Journal of Physiology: Endocrinology and Metabolism, 2000.
- Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Annals of Clinical and Laboratory Science, 2015.
- Lanthionine synthetase C-like protein 1 (LanCL1): a therapeutic target for neuropathic pain. Pain, 2026.
- Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. Drug Design, Development and Therapy, 2022.
